KalVista Pharmaceuticals (NASDAQ:KALV) Trading 8.7% Higher Following Analyst Upgrade

Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) shot up 8.7% on Thursday after Stifel Nicolaus raised their price target on the stock from $39.00 to $42.00. Stifel Nicolaus currently has a buy rating on the stock. KalVista Pharmaceuticals traded as high as $18.82 and last traded at $18.6350. 837,871 shares traded hands during mid-day trading, a decline of 16% from the average session volume of 1,000,371 shares. The stock had previously closed at $17.14.

A number of other analysts also recently issued reports on the stock. Needham & Company LLC raised their price target on shares of KalVista Pharmaceuticals from $35.00 to $36.00 and gave the company a “buy” rating in a report on Wednesday. Weiss Ratings reissued a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a report on Thursday, January 22nd. Citizens Jmp lowered their price objective on shares of KalVista Pharmaceuticals from $29.00 to $28.00 and set a “market outperform” rating on the stock in a research report on Thursday. HC Wainwright raised their target price on shares of KalVista Pharmaceuticals from $27.00 to $37.00 and gave the stock a “buy” rating in a report on Friday, January 9th. Finally, Wall Street Zen raised shares of KalVista Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, December 6th. Seven research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, KalVista Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $32.60.

Insider Buying and Selling at KalVista Pharmaceuticals

In other news, insider Nicole Sweeny sold 3,975 shares of the business’s stock in a transaction on Monday, February 23rd. The shares were sold at an average price of $15.57, for a total transaction of $61,890.75. Following the completion of the sale, the insider owned 47,003 shares of the company’s stock, valued at $731,836.71. The trade was a 7.80% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Paul K. Audhya sold 5,354 shares of the company’s stock in a transaction on Monday, February 23rd. The stock was sold at an average price of $15.57, for a total value of $83,361.78. Following the completion of the sale, the insider owned 138,983 shares of the company’s stock, valued at $2,163,965.31. This trade represents a 3.71% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 33,378 shares of company stock valued at $522,290. 4.30% of the stock is owned by corporate insiders.

Trending Headlines about KalVista Pharmaceuticals

Here are the key news stories impacting KalVista Pharmaceuticals this week:

• Positive Sentiment: Company reported $49.1M in EKTERLY revenue during an eight‑month transition period and highlighted a strong launch that supports topline growth expectations. KalVista posts $49.1 million in EKTERLY revenue
• Positive Sentiment: Corporate update and eight‑month FY2025 results emphasized commercial progress and operational updates that underpin near‑term revenue visibility. KalVista Reports Eight Months Fiscal Year 2025 Financial Results and Provides Corporate Update
• Positive Sentiment: Stifel Nicolaus raised its price target to $42 and kept a “buy” rating — implying ~122% upside from the current price — reflecting bullish analyst views on commercial execution and upside potential. Stifel raises KALV price target
• Positive Sentiment: Needham & Company increased its target from $35 to $36 and maintained a “buy” rating, signaling continued analyst confidence in EKTERLY’s market opportunity. Needham raises KALV price target
• Neutral Sentiment: Q1/8‑month earnings call transcripts (and related highlights) are available; these provide detail on revenue cadence, channel dynamics, and management commentary that investors should review for execution risk and guidance clarity. Q1 2025 earnings call transcript 8 Months 2025 earnings call transcript
• Negative Sentiment: Citizens Jmp trimmed its price target from $29 to $28 and moved to “market outperform” — a mild downgrade in target that could temper enthusiasm despite still-significant upside (~48%). Citizens Jmp lowers KALV price target

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in KALV. Seven Fleet Capital Management LP purchased a new stake in KalVista Pharmaceuticals in the 4th quarter worth approximately $782,000. Invesco Ltd. boosted its position in shares of KalVista Pharmaceuticals by 23.1% in the fourth quarter. Invesco Ltd. now owns 77,864 shares of the specialty pharmaceutical company’s stock worth $1,258,000 after purchasing an additional 14,621 shares during the period. XTX Topco Ltd purchased a new stake in shares of KalVista Pharmaceuticals in the fourth quarter worth $428,000. Vestal Point Capital LP raised its position in shares of KalVista Pharmaceuticals by 152.0% during the 4th quarter. Vestal Point Capital LP now owns 1,890,000 shares of the specialty pharmaceutical company’s stock valued at $30,524,000 after purchasing an additional 1,140,000 shares during the period. Finally, Virtus Investment Advisers LLC lifted its stake in shares of KalVista Pharmaceuticals by 364.9% during the 4th quarter. Virtus Investment Advisers LLC now owns 40,414 shares of the specialty pharmaceutical company’s stock valued at $653,000 after buying an additional 31,721 shares in the last quarter.

KalVista Pharmaceuticals Price Performance

The company has a debt-to-equity ratio of 8.18, a quick ratio of 7.21 and a current ratio of 7.22. The company has a market cap of $957.92 million, a P/E ratio of -4.80 and a beta of -0.35. The firm’s fifty day moving average is $15.95 and its two-hundred day moving average is $14.44.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.